Britain and America have concluded a significant bilateral deal that will guarantee zero import taxes on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the NHS. This pledge ensures that tariffs on these vital goods will stay at zero for a period of 36 months.
This agreement is in response to earlier warnings to significantly raise duties on branded drug products, with increases discussed up to one hundred percent.
"This agreement between the Britain reinforces the global environment for new treatments and brings much-needed equity to transatlantic drug exports," a release declared.
Trade Importance
Pharmaceuticals are one of the Britain's most significant exports to the US, which is clearly the largest market for leading UK drugmakers.
Export figures show that in the 12 months leading up to the third quarter, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that timeframe.
"This guarantee safeguards employment, stimulates capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official stated.
Specific UK Commitments
The agreement entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be limited at 15%. Last year, rebates were more than 20%.
Industry Background
This agreement follows a ongoing tension between the drug companies and the ministers over medicine costs and approval rates.
The disagreement were heightened by arguments that US consumers were charged a premium for the same drugs than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or cancelled, while substantial expansions have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
